Evidence map›Paper›PMID 40323277›Full record

ArticleFuture oncology (London, England)2025

DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients.

François Cherifi, Isabelle Ray-Coquard, Maria Jesus Rubio, Xavier Paoletti, Domenica Lorusso, Chel Hun Choi, Kosei Hasegawa, David Shao Peng Tan, Emma Hudson, Alison Davis and 6 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05201547 (Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05201547 phase3active not recruitingnot on this map

Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting

TypeinterventionalSponsorARCAGY/ GINECO GROUPRan2022 to 2029Enrolled260ConditionsEndometrial CancerArmsCarboplatin-Paclitaxel, Dostarlimab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

François CherifiClinical Research Department, Centre François Baclesse, Caen, France.ORCID 0000-0003-3842-7168
Isabelle Ray-CoquardLéon Bérard Center, University of Claude Bernard Lyon Est, Lyon, France.
Maria Jesus RubioServicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain.
Xavier PaolettiBiostatistic Unit, Institut Curie, Paris, France.
Domenica LorussoGynecologic Oncology Unit, Humanitas San Pio X, Milan, Italy.
Chel Hun ChoiSamsung Medical Center, Sungkyunkwan Univ, Gangnam-Gu, Republic of (South) Korea.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
David Shao Peng TanNational University Cancer Institute, National University Hospital and National University of Singapore (NUS) Centre for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Emma HudsonGynaecologic Oncology, Velindre Cancer Centre, Cardiff, WLS, UK.
Alison DavisDepartment of Medical Oncology, Canberra Hospital, Canberra, Australia.
Germana TognonUO Ostetricia-Ginecologia ASST Spedali Civili, Università degli Studi-Brescia, Brescia, Italy.
Stéphanie LheureuxPrincess Margaret Hospital, Department of Medical Oncology, Toronto, ON, Canada.
Mehmet Ali Vardar KeyDepartment of Gynecologic Oncology, Balcalı Hospital, Adana, Turkey.
Jean Emmanuel KurtzHaematology-Oncology Department, Centre Hospitalier Régional et Universitaire de Strasbourg Hôpital Civil, Strasbourg, France.
Jerome AlexandreMedical Oncology Department, AP-HP-centre Université de Paris Cité, Paris, France.
Florence JolyMedical Oncology Department, CHU de Caen, Caen, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy (IO) in endometrial cancer (EC) is the standard of care in the second line setting in combination with an anti-angiogenic agent. Randomized clinical trials have reported results supporting the addition of IO to chemotherapy (paclitaxel plus carboplatin) in the first-line setting in advanced EC patients in the global population, with high efficacy in mismatch repair deficient (MMRd) patients. These trials were not designed to answer this de-escalation question in the MMRd population, who benefit greatly from IO.The international, randomized phase III, DOMENICA trial compares first-line dostarlimab versus chemotherapy alone (with planned cross-over) for advanced MMRd EC. Our primary endpoint will be progression-free survival. The key secondary endpoints will be overall survival, safety and quality of life [NCT05201547].

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsCarboplatinClinical Trials, Phase III as TopicDNA Mismatch RepairFemaleHumansMulticenter Studies as TopicNeoplasm StagingPaclitaxelQuality of LifeRandomized Controlled Trials as TopicAntibodies, Monoclonal, HumanizedCarboplatindostarlimabPaclitaxeladvanced/metastaticde-escalationdostarlimabendometrial cancerimmunotherapyMismatch repair deficientprogression-free survivaltreatment-related biomarkers

Identifiers

PMID40323277
PMCPMC12140448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.